Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris - 09/08/11
Reprint requests: James J. Leyden, MD, KGL Skin Study Center, 505 Parkway, Broomall, PA 19008.Philadelphia, Pennsylvania, and Palo Alto, California
Abstract |
Background |
The development of a hydrogel to stabilize and solubilize clindamycin and tretinoin provides a single, once-daily treatment for acne vulgaris.
Objective |
Our aim was to compare the efficacy and safety of the combination of clindamycin (1%) and tretinoin (0.025%) with each agent alone and vehicle.
Methods |
Two randomized, double-blind, active drug– and vehicle-controlled 12-week studies evaluated inflammatory and noninflammatory lesion counts and the Investigator’s Static Global Assessment in 2219 subjects with acne vulgaris.
Results |
The combination demonstrated superior efficacy to clindamycin, tretinoin, and vehicle. Combination hydrogel was significantly more effective in reducing inflammatory (P < .005), noninflammatory (P ≤ .0004), and total (P < .0001) lesion counts than the other treatments and vehicle. The proportion of subjects with clear or almost clear skin on the Investigator’s Static Global Assessment was greater with the combination (P < .0001).
Limitations |
A majority of subjects (82.6%) had grade 2-3 acne vulgaris at baseline; therefore these overall results may not be representative of the response in the subjects (17.4%) with grade 4-5 acne.
Conclusion |
The combination clindamycin/tretinoin hydrogel was well tolerated and significantly more effective than clindamycin, tretinoin, or vehicle for the treatment of acne vulgaris.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Supported by Connetics Corporation. Disclosure: Dr Leyden is a consultant and/or member of an advisory board or speaker’s bureau for Allergan, Medicis, Galderma, Dermik, Connetics, CollaGenex, Stiefel, Ortho, and Fujisawa. Drs Yaroshinsky and Krochmal are employees of Connetics Corporation, and each holds stock in Connetics. Published online November 25, 2005. |
Vol 54 - N° 1
P. 73-81 - gennaio 2006 Ritorno al numero
Articolo precedente
- Treatment of recalcitrant atopic dermatitis with omalizumab
- Joshua E. Lane, Jason M. Cheyney, Tanda N. Lane, David E. Kent, David J. Cohen
- Use of high-dose acyclovir in pityriasis rosea
- Francesco Drago, Federica Vecchio, Alfredo Rebora
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?